A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer

Krishna Rao; Sini Kalapurakal; Pratima Chalasani; Kathy Robinson; James Malone; Cathy Clausen; Ohad Ronen; Muthuswamy Dhiwakar; Bruce Shevlin; K. Thomas Robbins

doi:10.1007/s00280-013-2225-7

A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer

Krishna Rao, Sini Kalapurakal, Pratima Chalasani, Kathy Robinson, James Malone, Cathy Clausen, Ohad Ronen, Muthuswamy Dhiwakar, Bruce Shevlin, K. Thomas Robbins

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Background: Based on the convenient oral dosing of erlotinib and the promising results of biologic therapy, we undertook a phase II study with 21 patients with locally advanced (T3-4) lesions combining radiation with intra-arterial (IA) cisplatin and oral daily erlotinib for a 7-week therapy. Methods: Treatment for the primary tumor and upper neck was given to a total dose of 70 Gy. Chemotherapy with IA cisplatin (150 mg/m²) was given on days 1, 8, 15, and 22 concurrently with radiotherapy. During the 7-week treatment period, patients were given erlotinib 150 mg/day. Results: Overall survival is 63 %, and the relapse/persistent disease rate stands at 36.8 %. A total of 15.2 % of serious adverse event was considered related to erlotinib. Conclusion: Our study and several others now demonstrate the feasibility of combining anti-epidermal growth factor receptor (EGFR) therapy with chemoradiation, hint at improved survival outcomes with reduced distant metastatic rates, and suggest that maintenance therapy with anti-EGFR agent may be beneficial.

Original language	English
Pages (from-to)	545-552
Number of pages	8
Journal	Cancer Chemotherapy and Pharmacology
Volume	72
Issue number	3
DOIs	https://doi.org/10.1007/s00280-013-2225-7
State	Published - Sep 2013
Externally published	Yes

Bibliographical note

Funding Information:
Acknowledgments We greatly appreciate the efforts of our clinical research office staff who made the performance of this trial possible and successful. We also gratefully acknowledge the support from Genentech Corporation for this study. They provided study funding for the trial.

Funding

Acknowledgments We greatly appreciate the efforts of our clinical research office staff who made the performance of this trial possible and successful. We also gratefully acknowledge the support from Genentech Corporation for this study. They provided study funding for the trial.

Funders	Funder number
Genentech

Keywords

Cisplatin
Erlotinib
Head and neck cancer
Radiation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-013-2225-7

Cite this

@article{09d0bf820f61424b8ea972d5d927097d,

title = "A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer",

abstract = "Background: Based on the convenient oral dosing of erlotinib and the promising results of biologic therapy, we undertook a phase II study with 21 patients with locally advanced (T3-4) lesions combining radiation with intra-arterial (IA) cisplatin and oral daily erlotinib for a 7-week therapy. Methods: Treatment for the primary tumor and upper neck was given to a total dose of 70 Gy. Chemotherapy with IA cisplatin (150 mg/m2) was given on days 1, 8, 15, and 22 concurrently with radiotherapy. During the 7-week treatment period, patients were given erlotinib 150 mg/day. Results: Overall survival is 63 %, and the relapse/persistent disease rate stands at 36.8 %. A total of 15.2 % of serious adverse event was considered related to erlotinib. Conclusion: Our study and several others now demonstrate the feasibility of combining anti-epidermal growth factor receptor (EGFR) therapy with chemoradiation, hint at improved survival outcomes with reduced distant metastatic rates, and suggest that maintenance therapy with anti-EGFR agent may be beneficial.",

keywords = "Cisplatin, Erlotinib, Head and neck cancer, Radiation",

author = "Krishna Rao and Sini Kalapurakal and Pratima Chalasani and Kathy Robinson and James Malone and Cathy Clausen and Ohad Ronen and Muthuswamy Dhiwakar and Bruce Shevlin and Robbins, {K. Thomas}",

note = "Funding Information: Acknowledgments We greatly appreciate the efforts of our clinical research office staff who made the performance of this trial possible and successful. We also gratefully acknowledge the support from Genentech Corporation for this study. They provided study funding for the trial.",

year = "2013",

month = sep,

doi = "10.1007/s00280-013-2225-7",

language = "אנגלית",

volume = "72",

pages = "545--552",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "3",

}

TY - JOUR

T1 - A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer

AU - Rao, Krishna

AU - Kalapurakal, Sini

AU - Chalasani, Pratima

AU - Robinson, Kathy

AU - Malone, James

AU - Clausen, Cathy

AU - Ronen, Ohad

AU - Dhiwakar, Muthuswamy

AU - Shevlin, Bruce

AU - Robbins, K. Thomas

N1 - Funding Information: Acknowledgments We greatly appreciate the efforts of our clinical research office staff who made the performance of this trial possible and successful. We also gratefully acknowledge the support from Genentech Corporation for this study. They provided study funding for the trial.

PY - 2013/9

Y1 - 2013/9

N2 - Background: Based on the convenient oral dosing of erlotinib and the promising results of biologic therapy, we undertook a phase II study with 21 patients with locally advanced (T3-4) lesions combining radiation with intra-arterial (IA) cisplatin and oral daily erlotinib for a 7-week therapy. Methods: Treatment for the primary tumor and upper neck was given to a total dose of 70 Gy. Chemotherapy with IA cisplatin (150 mg/m2) was given on days 1, 8, 15, and 22 concurrently with radiotherapy. During the 7-week treatment period, patients were given erlotinib 150 mg/day. Results: Overall survival is 63 %, and the relapse/persistent disease rate stands at 36.8 %. A total of 15.2 % of serious adverse event was considered related to erlotinib. Conclusion: Our study and several others now demonstrate the feasibility of combining anti-epidermal growth factor receptor (EGFR) therapy with chemoradiation, hint at improved survival outcomes with reduced distant metastatic rates, and suggest that maintenance therapy with anti-EGFR agent may be beneficial.

AB - Background: Based on the convenient oral dosing of erlotinib and the promising results of biologic therapy, we undertook a phase II study with 21 patients with locally advanced (T3-4) lesions combining radiation with intra-arterial (IA) cisplatin and oral daily erlotinib for a 7-week therapy. Methods: Treatment for the primary tumor and upper neck was given to a total dose of 70 Gy. Chemotherapy with IA cisplatin (150 mg/m2) was given on days 1, 8, 15, and 22 concurrently with radiotherapy. During the 7-week treatment period, patients were given erlotinib 150 mg/day. Results: Overall survival is 63 %, and the relapse/persistent disease rate stands at 36.8 %. A total of 15.2 % of serious adverse event was considered related to erlotinib. Conclusion: Our study and several others now demonstrate the feasibility of combining anti-epidermal growth factor receptor (EGFR) therapy with chemoradiation, hint at improved survival outcomes with reduced distant metastatic rates, and suggest that maintenance therapy with anti-EGFR agent may be beneficial.

KW - Cisplatin

KW - Erlotinib

KW - Head and neck cancer

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=84883489494&partnerID=8YFLogxK

U2 - 10.1007/s00280-013-2225-7

DO - 10.1007/s00280-013-2225-7

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 23884559

AN - SCOPUS:84883489494

SN - 0344-5704

VL - 72

SP - 545

EP - 552

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 3

ER -

A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this